Takahashi N, Kadota T, Kawano S, Ishikawa K, Kuroyanagi K, Hamajima Y, Ohta K, Ohta S, Kai S, Kohmura H
J Toxicol Sci. 1986 Apr;11 Suppl 1:1-16. doi: 10.2131/jts.11.supplementi_1.
VP 16-213 (etoposide, abbr. to VP), an oncostatic drug, was examined for its oral, subcutaneous or intravenous acute toxicity using Slc : ICR mice, Crj : CD (Sprague-Dawley) rats and JW-NIBS rabbits of both sexes. The summarized results obtained are as follows: A mode of manifestation of toxic effects was classified into immediate-type symptoms predominantly caused by the carrier and delayed-type symptoms predominantly caused by VP regardless of animal species and routes of administration, excluding the case of intravenous dosing to rabbits. Referring to the delayed-type toxic signs, depilation, diarrhea and suppression of body weight increase were observed for mice and rats regardless of administration routes, and diarrhea was noted in rabbits by oral route. Necropsy of three species of animals and histopathology on rabbits revealed thymic and splenic atrophy in mice and rats as well as thymic atrophy and inflammatory changes of intestine in rabbits dying by oral administration. The drug-related cause of death for mice and rats seemed to be due to the cytocidal action of VP as an oncostatic drug, but the cause of death for rabbits by oral administration was considered to be somewhat different from that for mice and rats. LD50 values (mg/kg) were as follows, showing oral toxicity in rabbits being rather potent as compared with that in mice or rats: (table; see text).
依托泊苷(VP 16 - 213,简称VP)是一种抗癌药物,使用日本实验动物中央研究所的ICR小鼠、日本Charles River公司的CD(斯普拉格 - 道利)大鼠以及JW - NIBS家兔,对其进行了口服、皮下或静脉注射的急性毒性试验,涉及雌雄两性动物。总结结果如下:毒性作用的表现模式分为主要由载体引起的速发型症状和主要由VP引起的迟发型症状,无论动物种类和给药途径如何,但静脉注射家兔的情况除外。关于迟发型毒性体征,无论给药途径如何,小鼠和大鼠均出现脱毛、腹泻和体重增加抑制,经口给药的家兔出现腹泻。对三种动物进行尸检以及对家兔进行组织病理学检查发现,口服给药死亡的小鼠和大鼠出现胸腺和脾脏萎缩,家兔出现胸腺萎缩和肠道炎症变化。小鼠和大鼠与药物相关的死亡原因似乎是由于VP作为抗癌药物的杀细胞作用,但经口给药的家兔的死亡原因被认为与小鼠和大鼠有所不同。半数致死量(LD50)值(mg/kg)如下,显示家兔的经口毒性与小鼠或大鼠相比相当强:(表格;见正文)